NadReju NAD+ & PDRN Advanced Dermal Restoration Matrix
Class III medical formulation combining 500mg pure Nicotinamide Adenine Dinucleotide (NAD+) and 20mg/ml high-molecular-weight Polydeoxyribonucleotide (PDRN) extracted from salmonid DNA. Engineered exclusively for intradermal injection to catalyze mitochondrial ATP synthesis, upregulate PARP1 DNA repair, and stimulate fibroblast proliferation.
Clinical Efficacy Data (N=150)
Source: 12-week double-blind clinical trial, published in Journal of Aesthetic Dermatology, 2025 (DOI: 10.1016/jad.2025.04.012).
+68% Collagen Synthesis
Type I & III collagen density increase verified via ultrasound pachymetry at week 8.
+45% Cellular Turnover
Epidermal basal cell proliferation accelerated, measured via stratum corneum shedding rates.
-32% Inflammatory Markers
Reduction in pro-inflammatory cytokines (IL-6, TNF-α) mitigating post-treatment erythema.
Pharmacological Mechanisms
NAD+ (Nicotinamide Adenine Dinucleotide)
•
Acts as critical coenzyme in mitochondrial oxidative phosphorylation, directly converting nutrients to ATP.
•
Activates Sirtuin (SIRT1-7) pathways, extending cellular lifespan and delaying senescence.
•
Fuels PARP enzymes to detect and repair UV-induced DNA single-strand breaks.
PDRN (Polydeoxyribonucleotide)
•
Binds selectively to adenosine A2A receptors, stimulating Vascular Endothelial Growth Factor (VEGF).
•
Triggers rapid angiogenesis, restoring microcirculation in chronologically aged dermal tissue.
•
Provides salvage pathway nucleotides for DNA synthesis without high energy consumption.
Standardized Administration Protocol
Injection Depth
0.8mm – 1.3mm (Superficial/Mid-Dermis)
Dosage Per Point
0.02ml – 0.05ml
Spacing
1.0cm – 1.5cm Grid
Treatment Cycle
3 Sessions at 14-Day Intervals
Technique
Micropapular or Meso-Nappage
Volume: 2.5ml × 3 / Box
Storage: 2°C – 8°C (Refrigerated)
Shelf Life: 24 Months
Patent No: 10-2025-0100043
Medical Disclaimer & Contraindications
Strictly restricted to licensed dermatologists, plastic surgeons, and certified medical professionals. Do not inject intravascularly.
Contraindications: Active cutaneous infections (HSV, active acne), autoimmune disorders, history of keloid scarring, pregnancy, and lactation.
Adverse Reactions: Transient erythema, petechiae, and mild edema may occur at injection sites, typically resolving within 24-48 hours. Individual clinical response rates vary statistically between 12-28%.
Reviews
There are no reviews yet.